Horizon Pharma plc and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE(R) (interferon gamma-1b) in Combination With Nivolumab in Patients With Advanced Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Horizon Pharma plc and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE(R) (interferon gamma-1b) in Combination With Nivolumab in Patients With Advanced Solid Tumors

Mizuho Securities Raises Price Target to $36 Following Horizon Pharma's (HZNP) Announced Crealta Deal

December 14, 2015 8:15 AM EST

Mizuho Securities reiterated a Buy rating on Horizon Pharma (NASDAQ: HZNP), and raised the price target to $36.00 (from $34.00), following the Crealta announcement. Horizon plans to acquire Crealta, a private company selling Krystexxa, a third line, Orphan biologic for the treatment of chronic,... More